Calamos Wealth Management’s AstraZeneca AZN Stock Holding History

Calamos Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.37M	Buy	27,227 +11,452	+73%	+$2.21M	0.18%	91
2025 Q4	$2.9M	Buy	+15,775	New	+$2.77M	0.1%	109
2024 Q1	–	Sell	-9,137	Closed	-$1.23M	–	318
2023 Q4	$1.23M	Sell	9,137 -2,925	-24%	-$380K	0.08%	123
2023 Q3	$1.63M	Buy	12,062 +4,156	+53%	+$568K	0.12%	104
2023 Q2	$1.13M	Sell	7,906 -126	-2%	-$18.5K	0.08%	131
2023 Q1	$1.12M	Buy	8,032 +667	+9%	+$89.7K	0.09%	124
2022 Q4	$999K	Sell	7,365 -7,790	-51%	-$977K	0.08%	141
2022 Q3	$1.66M	Sell	15,155 -1,356	-8%	-$172K	0.14%	106
2022 Q2	$2.18M	Buy	+16,511	New	+$2.17M	0.19%	95

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Calamos Wealth Management's AZN Position: Q1 2026 in Review

Calamos Wealth Management increased its AstraZeneca (AZN) stake by 73% in Q1 2026, buying an estimated $2.21M and bringing the position to 27,227 shares worth $5.37M. The position accounts for 0.18% of the portfolio, ranked #91.

Calamos Wealth Management first reported a position in AZN in Q2 2022 and has held it in 9 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Calamos Wealth Management held 27,227 shares of AstraZeneca worth $5.37M as of Q1 2026.
Calamos Wealth Management bought 11,452 AstraZeneca shares in Q1 2026, an estimated $2.21M.
AstraZeneca made up 0.18% of Calamos Wealth Management's portfolio in Q1 2026, its #91 holding.
Calamos Wealth Management first reported a position in AstraZeneca in Q2 2022 and has held it in 9 quarters since.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Calamos Wealth Management's 13F filing for Q1 2026, filed 4 May 2026.